在患有喘和肺扩散能力降低的患者中,对生物疗法的反应
Leonie Biener1, Hussein Morobeid1, Carmen Pizarro1
1Department of Internal Medicine II, Cardiology, Pneumology, Angiology, University Hospital of Bonn, Bonn, Germany.
Respiration; international review of thoracic diseases
|September 9, 2024
概括
生物疗法有效地治疗喘,即使肺部对一氧化碳 (DLCO) 的扩散能力降低. 这些发现表明,DLCO测量不应阻碍接受生物制剂的患者的喘诊断或治疗.
科学领域:
- 肺部病理学 肺部病理学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘试验往往排除有吸烟史的患者,以避免混COPD等并发症.
- 关于喘患者的生物治疗疗效的数据有限,肺部对一氧化碳 (DLCO) 的扩散能力降低.
研究的目的:
- 为了评估生物治疗在喘患者的有效性,这些患者已经减少了DLCO.
- 为了确定DLCO水平是否会影响接受生物治疗的喘患者的治疗反应.
主要方法:
- 分析了接受生物治疗的77名喘患者的队列.
- 根据DLCO水平和吸烟史 (包装年) 将患者分为三组.
- 治疗反应在至少6个月的随访后进行评估.
主要成果:
- 在所有组中观察到可比的治疗反应,包括急性恶化率和口服皮质类固醇剂量减少.
- 在DLCO水平和喘控制测试 (ACT) 成绩或FEV1.1的改善之间没有发现显著的相关性.
- 在一小部分患者中,降低的转移系数 (DLCO/VA) 并没有显著影响治疗结果.
结论:
- 生物疗法在控制喘方面表现出有效性,无论DLCO测量如何.
- 降低DLCO不应成为全面喘诊断和治疗的障碍.
- 建议对DLCO/VA在评估喘治疗反应中的作用进行进一步的研究.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
362
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
362
COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
Antiasthma Drugs: β2-Adrenoceptor Agonists
239
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
239
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
246
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
246
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
228
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
228
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K


